Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference
July 08 2022 - 7:00AM
Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading
late-stage, clinical biotechnology company advancing an integrated
and sustainable pipeline of genetic therapies for rare childhood
disorders with high unmet need, today announces that Gaurav Shah,
M.D., Chief Executive Officer, will participate in a fireside chat
at the William Blair Biotech Focus Conference 2022 on July 12-13,
2022, at the St. Regis Hotel in New York City. Management will also
be hosting one-on-one meetings with investors.
The pre-recorded fireside chat will be available beginning
Monday, July 11, 2022, at 9:00 a.m. ET. A link to the recording
will be available under “Events” in the Investors section of the
Company’s website at https://ir.rocketpharma.com. The webcast
replay will be available to view for 30 days via the Rocket website
following the conference.
The presentation will highlight the Company’s pipeline of
first-in-class gene therapies that incorporate both
adeno-associated viral vector (AAV) and lentiviral vector (LVV)
approaches to gene therapy. The Company recently announced positive
top-line safety and efficacy data from its Phase 2 pivotal trial
for severe Leukocyte Adhesion Deficiency-I (LAD-I), as well
positive clinical updates from its Phase 2 pivotal trial for
Fanconi Anemia (FA) and Phase 1 trials for Danon Disease and
Pyruvate Kinase Deficiency (PKD).
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an
integrated and sustainable pipeline of genetic therapies that
correct the root cause of complex and rare childhood disorders. The
Company’s platform-agnostic approach enables it to design the best
therapy for each indication, creating potentially transformative
options for patients afflicted with rare genetic diseases. Rocket's
clinical programs using lentiviral vector (LVV)-based gene therapy
are for the treatment of Fanconi Anemia (FA), a difficult-to-treat
genetic disease that leads to bone marrow failure and potentially
cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric
genetic disorder that causes recurrent and life-threatening
infections that are frequently fatal, and Pyruvate Kinase
Deficiency (PKD), a rare, monogenic red blood cell disorder
resulting in increased red cell destruction and mild to
life-threatening anemia. Rocket’s first clinical program using
adeno-associated virus (AAV)-based gene therapy is for Danon
Disease, a devastating, pediatric heart failure condition. For more
information about Rocket, please visit www.rocketpharma.com.
Rocket Cautionary Statement Regarding Forward-Looking
Statements
Various statements in this release concerning Rocket’s future
expectations, plans and prospects, including, without limitation,
Rocket’s expectations regarding its guidance for 2022 in light of
COVID-19, the safety and effectiveness of product candidates that
Rocket is developing to treat Fanconi Anemia (FA), Leukocyte
Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD),
and Danon Disease, the expected timing and data readouts of
Rocket’s ongoing and planned clinical trials, Rocket’s plans for
the advancement of its Danon Disease program following the lifting
of the FDA’s clinical hold and the safety, effectiveness and timing
of related pre-clinical studies and clinical trials, and Rocket’s
plans for the advancement of its LAD-I program based on the data
presented at ASGCT and the potential for therapeutic benefit
related thereto, may constitute forward-looking statements for the
purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995 and other federal securities laws and
are subject to substantial risks, uncertainties and assumptions.
You should not place reliance on these forward-looking statements,
which often include words such as "believe," "expect,"
"anticipate," "intend," "plan," "will give," "estimate," "seek,"
"will," "may," "suggest" or similar terms, variations of such terms
or the negative of those terms. Although Rocket believes that the
expectations reflected in the forward-looking statements are
reasonable, Rocket cannot guarantee such outcomes. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including,
without limitation, Rocket’s ability to monitor the impact of
COVID-19 on its business operations and take steps to ensure the
safety of patients, families and employees, the interest from
patients and families for participation in each of Rocket’s ongoing
trials, our expectations regarding the delays and impact of
COVID-19 on clinical sites, patient enrollment, trial timelines and
data readouts, our expectations regarding our drug supply for our
ongoing and anticipated trials, actions of regulatory agencies,
which may affect the initiation, timing and progress of
pre-clinical studies and clinical trials of its product candidates,
Rocket’s dependence on third parties for development, manufacture,
marketing, sales and distribution of product candidates, the
outcome of litigation, and unexpected expenditures, as well as
those risks more fully discussed in the section entitled "Risk
Factors" in Rocket’s Annual Report on Form 10-K for the year ended
December 31, 2021, filed February 28, 2022 with the SEC.
Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of
the date made, and Rocket undertakes no obligation to update or
revise publicly any forward-looking statements, whether as a result
of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220708005060/en/
Media Kevin Giordano Director, Corporate Communications
kgiordano@rocketpharma.com Investors Jessie Yeung, M.B.A.
Vice President, Investor Relations and Corporate Finance
investors@rocketpharma.com
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Sep 2023 to Sep 2024